X-Chem, Inc. and AstraZeneca have entered into an expanded global drug discovery collaboration across all of AZ’s therapeutic areas and multiple target classes. AstraZeneca recently licensed three drug discovery programs from a previous collaboration with X-Chem, directed at an oncology protein-protein interaction (PPI) target, a respiratory/inflammation PPI target, and an antibacterial target. AstraZeneca extended the initial research collaboration to five years and X-Chem will conduct drug dis...